On 19 JUNE Idenix Pharmaceuticals Inc (NASDAQ:IDIX) said its shares jumped 230% when Merck announced that it would buy biotech company for its hepatitis C treatment. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) weekly performance is 0.02%. On last trading day company shares ended up $24.00. Analysts mean target price for the company is $14.88. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) distance from 50-day simple moving average (SMA50) is 127.56%.
On 24 JUNE bluebird bio Inc (NASDAQ:BLUE) reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.12. The company had revenue of $6.30 million for the quarter, compared to the consensus estimate of $6.23 million. On average, analysts predict that bluebird bio will post $-1.78 earnings per share for the current fiscal year. bluebird bio Inc (NASDAQ:BLUE) shares advanced 1.67% in last trading session and ended the day on $40.18. BLUE return on assets is -13.10%. bluebird bio Inc (NASDAQ:BLUE) quarterly performance is 78.74%.
On 2 JUNE Theravance Inc (NASDAQ:THRX) and Theravance Biopharma, Inc. announced the completion of the separation of Theravance Biopharma, Inc., the research and development-based biopharmaceutical business, from Theravance, Inc. to form two, independent, publicly traded companies with differing business objectives and opportunities, via a dividend distribution of Theravance Biopharma shares to Theravance stockholders. Theravance Inc (NASDAQ:THRX) shares moved up 0.27% in last trading session and was closed at $29.93, while trading in range of $29.27 – $30.00. Theravance Inc (NASDAQ:THRX) year to date (YTD) performance is 4.18%.
On 16 JUNE Sequenom, Inc. (NASDAQ:SQNM) and Quest Diagnostics (NYSE:DGX) announced an agreement under which Quest will offer national access to Sequenom Laboratories’ MaterniT21? PLUS laboratory-developed test (LDT). Using a maternal blood sample, the noninvasive prenatal test (NIPT) analyzes chromosomal material in cell-free fetal DNA of pregnant women at increased risk for fetal chromosomal abnormalities. Quest expects to begin offering access to the test in the third quarter. Sequenom, Inc. (NASDAQ:SQNM) ended the last trading day at $3.78. Company weekly volatility is calculated as 5.33% and price to cash ratio as 7.82. Sequenom, Inc. (NASDAQ:SQNM) showed a positive weekly performance of 4.42%.